Sponsor or institution

Clinical trials and research at Grit Biotechnology

• 15Clinical trials
• 1Country

Newest trials

All recruiting trials (15)

• GT801 injection for moderate-to-severe refractory autoimmune disease

  This trial will test whether GT801 injections are safe and help adults with moderate-to-severe autoimmune disease that has not responded to standard treatments.

  Recruiting Early Phase 1 Grit Biotechnology · Shanghai, Shanghai Municipality · NCT07333118

• GT729 universal cell injection for refractory or relapsed chronic graft-versus-host disease

  This trial will try GT729 universal cell injections in adults whose chronic graft-versus-host disease has not responded to at least two prior systemic treatments after an allogeneic stem cell transplant.

  Recruiting Early Phase 1 Grit Biotechnology · Tianjin, Tianjin Municipality · NCT07253259

• GT801 injection for adults with relapsed/refractory CD19-positive B-cell cancers and autoimmune hemolytic anemia

  This trial will test whether GT801 injections help adults with CD19-positive B-cell cancers (B-ALL, CLL, B-NHL) or autoimmune hemolytic anemia that have returned or not responded to prior treatments.

  Recruiting Early Phase 1 Grit Biotechnology · Zhengzhou, Henan and 1 other locations · NCT07205315

• GT719 injection for people with moderate to severe refractory autoimmune disease.

  This trial will test whether GT719 injections are safe and can help adults aged 18-65 whose moderate to severe autoimmune disease has not responded to other treatments.

  Recruiting Early Phase 1 Grit Biotechnology · Nantong, Jiangsu · NCT07132112

• GT719 universal cell injection for adults with relapsed or refractory CD19-positive B-cell cancers

  This trial will test whether GT719, a universal CD19-targeting cell injection, is safe and can induce remissions in adults with relapsed or refractory CD19-positive B-cell lymphoma or B-cell acute lymphoblastic leukemia.

  Recruiting Early Phase 1 Grit Biotechnology · Ganzhou, Jiangxi · NCT07131254

• GT719 injection for adults with moderate to severe refractory autoimmune diseases

  This trial will try giving GT719 injections to 10 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments to see if the treatment is safe and helps control their disease.

  Recruiting Early Phase 1 Grit Biotechnology · Shanghai · NCT07122076

• GT719 injection for recurrent or refractory antibody-mediated neurological autoimmune disease

  This trial will try an experimental cell therapy called GT719 in adults with recurrent or treatment-resistant antibody-mediated neurological autoimmune diseases to see if it is safe and may help disease activity.

  Recruiting Phase 1 Grit Biotechnology · Wuhan, Hubei · NCT07021209

• Treatment for recurrent CD19 positive adult B-cell cancers

  This study is testing a new injection to see if it can help adults with certain types of B-cell cancers that have come back or didn't respond to other treatments.

  Recruiting Phase 1/2 Grit Biotechnology · Tianjin, Tianjin Municipality · NCT06948981

• IB-T101 injection for advanced clear cell kidney cancer

  This study is testing a new injection called IB-T101 to see if it can help adults with advanced clear cell kidney cancer feel better and respond well to treatment.

  Recruiting Phase 1 Grit Biotechnology · Wuhan, Hubei · NCT06819293

• Using immune cells to treat advanced colorectal cancer

  This study is testing if injections of immune cells can help people with advanced colorectal cancer who haven't responded to other treatments feel better and improve their health.

  Recruiting Grit Biotechnology · Shanghai, Shanghai Municipality · NCT06819280

• Using immune cells to treat solid tumors in adults

  This study is testing if injections of immune cells can help adults with advanced ovarian cancer feel better after their initial chemotherapy.

  Recruiting Grit Biotechnology · Shanghai, Shanghai Municipality · NCT06453057

• Using GT307 injection to treat solid tumors

  This study is testing a new injection called GT307 to see if it can safely help people with advanced solid tumors feel better.

  Recruiting at 3 sites Grit Biotechnology · Beijing, Beijing Municipality and 2 other locations · NCT06397963

• Using immune cells to treat recurrent or metastatic cervical cancer

  This study is testing if a new immune cell treatment can work better than a standard chemotherapy drug for people with recurrent or metastatic cervical cancer.

  Recruiting at 31 sites Phase 2 Grit Biotechnology · Beijing, Beijing Municipality and 37 other locations · NCT06241781

• Using GT201 with PD-1 inhibitors for advanced head and neck tumors

  This study is testing if a new treatment called GT201, when used with a PD-1 inhibitor, can be safe and effective for people with advanced head and neck tumors.

  Recruiting Grit Biotechnology · Shanghai, Shanghai Municipality · NCT06190275

• GT201 injection for advanced solid tumors

  This study is testing a new injection called GT201 to see if it can safely help people with advanced solid tumors who haven't had any local treatments before.

  Recruiting at 6 sites Phase 1/2 Grit Biotechnology · Guangzhou, Guangdong and 5 other locations · NCT06144671

Quick answers

How many clinical trials run by Grit Biotechnology are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Early Phase 1: 6, Phase 1: 2, Phase 1/2: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →